lest ................... United States Patent Application 20190008989 - Publication Date : 01/10/2019 -

METHOD FOR UPREGULATING ANTIGEN EXPRESSION

There was an increase in CD20 expression by around 130% vs. untreated control for most time points.................... Treatment with BETALUTIN, anti-CD37 targeting Antibody Radionuclide Conjugate, increased the tumor uptake by 3 times while keeping uptake in normal organs constant as compared with mice treated with cold HH1......................It was also an unexpected finding that low dose rate radioimmunotherapy using 177Lu-HH-1 against CD37 antigen positive cells not only caused increase in antigen expression in cancer cells but also caused a prolonged effect compared to published data for external beam exposure.....................A new way of using targeted antibody therapy can be envisioned, i.e., induction therapy with radioimmunotherapy followed by antibody or antibody-conjugate therapy in the following days and weeks to exploit the increased antigen expression.........................

http://www.freepatentsonline.com/y2019/0008989.html

Børsmedlding om avlesningen av de 50 første (25 i hver arm ) i Paradigme kommer ikke. Pasientene skal overføres til den beste armen. Resultatene samles inn av ICON og sendes Nordic Nanovecter. Hvem får da se resultatene, og hvilken børsmelding kommer da..................